Conference Chair: Alan T. Remaley, MD, PhD, National Institutes of Health—NHLBI
Vice Chair: Gregory S. Graf, PhD,
University of Kentucky

2014 Program Schedule

Wednesday, September 10, 2014

7:00 PM: Arrival and Registration


Thursday, September 11, 2014

7:00 – 7:50 AM: Registration and Continental Breakfast

7:50 – 8:00 AM: Welcome and Opening — Alan T. Remaley, MD. PhD


Session 1: HDL, Cholesterol Transport and Inflammation
Moderator: Mary G. Sorci Thomas, PhD, Wake Forest University

8:00 – 8:30 AM: Jonathan D. Smith, PhD, Cleveland Clinic

  • Mechanism of HDL biogenesis

8:30 – 9:00 AM: Ricquita Pollard, Wake Forest University

  • Role of PCPE2 in HDL function

9:00 – 9:30 AM: Daisy Sahoo, PhD, Medical College of Wisconsin

  • Interactions of HDL with scavenger receptors: the good, the bad and the ugly

9:30 – 10:00 AM: Janusz H. Kabarowski, PhD, University of Alabama at Birmingham

  • Mechanism of apoA-I mediated immunosuppression

10:00 AM – 10:30 AM: BREAK


Session 2: Non-coding RNAs in Lipid Metabolism
Moderator: Kasey Vickers, PhD, Vanderbilt University

10:30 – 11:00 AM: Praveen Sethupathy, PhD, University of North Carolina at Chapel Hill

  • MicroRNA control of lipid homeostasis through epigenetic mechanisms

11:00 – 11:30 AM: Charles D. Searles Jr., MD, Emory University

  • Intercellular communication by encapsulated microRNAs is altered by coronary heart disease

11:30 – 12:00 PM: Amy S. Major, PhD, Vanderbilt University

  • Interactions of HDL with Scavenger Receptors: the good, the bad and the ugly

12:00 – 12:30 PM: Haiming Cao, PhD, National Heart, Lung and Blood Institute, National Institutes of Health

  • A liver-enriched long non-coding RNA regulates systemic lipid metabolism

10:00 AM – 10:30 AM: BREAK


3:30 – 5:00 PM: SPECIAL EDUCATIONAL SESSION ON CAREER TRANSITIONS: Faculty Participants, TBA

5:30 – 7:30 PM: POSTER SESSION and RECEPTION


8:00 PM – 9:15 PM: W. VIRGIL BROWN KEYNOTE LECTURE

A Brief History of HDL: Have We Learned Anything Substantial?

Jere P. Segrest, MD, PhD

Professor, Department of Medicine
University of Alabama at Birmingham


Friday, September 12, 2014

7:00 – 8:00 AM: Continental Breakfast

Session 3: Cardiovascular Biomarkers
Moderator: Peter W. F. Wilson, MD, Emory University

8:00 – 8:30 AM: Peter W. F. Wilson, MD,Emory University

  • New ATP4 cardiovascular guidelines

8:30 – 9:00 AM: Szilard Voros, MD, Stony Brook University & Global Genomics Group, LLC

  • Leveraging precision phenotyping and panomics to gain new insight into the biology of atherosclerosis

9:00 – 9:30 AM: James D. Otvos, PhD, North Carolina State University & LipoScience Corp.

  • NMR analysis of lipoprotein particle number and size for cardiovascular  risk assessment

9:30 – 10:00 AM: Hubert W. Vesper, PhD, Centers for Disease Control and Prevention

  • CDC Lipid Standardization Program to improve and ensure the accuracyof cardiovascular biomarker testing in patient care and research

10:00 AM – 10:30 AM: BREAK


Session 4: Lipoprotein Biology
Moderator: Nancy R. Webb, PhD, University of Kentucky

10:30 – 11:00 AM: Edward B. Neufeld, PhD, National Heart, Lung and Blood Institute, National Institutes of Health

  • ABCG1 at the plasma membrane and late endocytic compartments mobilizes non-sphingomyelin-associated pools of cholesterol for esterification and efflux

11:00 – 11:30 AM: Xiang-an Li, PhD, University of Kentucky

  • A novel function of HDL: regulating thymocyte apoptosis in sepsis

11:30 – 12:00 PM: Ryan Allen, PhD, Vanderbilt University

  • Control of very-low density lipoprotein secretion by microRNA-33

12:00 – 12:15 PM: Jianing Li, BS, University of Kentucky

  • Biliary vs. intestinal elimination of cholesterol

12:15 – 12:30 PM: Mingxia Liu, PhD, Wake Forest University

  • ApoM signal peptide is necessary for formation of large apoM/S1P-enriched HDL particles

12:30 – 3:30 PM: LUNCH & FREE TIME

3:30 – 5:00 PM: CHALK TALK FOR POST-DOCTORAL FELLOWS (light refreshments provided)


Session 5: New Cardiovascular Therapies
Moderator: Michael H. Davidson, MD, University of Chicago

5:30 – 6:00 PM: Michael H. Davidson, MD, University of Chicago

  • Emerging therapies for dyslipidemia

6:00 – 6:30 PM: Marcelo J. Amar, MD, National Heart, Lung and Blood Institute, National Institutes of Health

  • PCSK9 vaccine for lowering LDL-C

6:30 – 7:00 PM: Roger S. Newton, PhD, Esperion Therapeutics

  • Dynamics of lipoproteins and cholesterol

7:00 – 7:30 PM: Norman C. W. Wong, PhD, University. of Calgary & Resverlogix

  • RVX-208; a BET inhibitor, up regulates apoA-1 in human clinical trials

7:30 PM: DINNER ON YOUR OWN


Saturday, September 13, 2014

7:00 - 8:00 AM: Continental Breakfast

Session 6: Bioactive Lipids
Moderator: Christopher E. Ramsden, MD, National Institute on Alcohol Abuse and Alcoholism, NIH

8:00 – 8:30 AM:Christopher E. Ramsden, MD, National Institute on Alcohol Abuse and Alcoholism, NIH

  • Dietary modulation of nociceptive mediators and physical pain

8:30 – 9:00 AM: Zhen-Zhong Xu, PhD, Duke University Medical Center

  • Anti-nociceptive lipid mediators

9:00 – 9:30 AM: Laurence S. Sperling, MD, Emory University

  • Omega 3's and CVD: something fishy?

9:30 – 10:00 AM: Joseph R. Hibbeln, MD, National Institute on Alcohol Abuse and Alcoholism, NIH

  • Lipid mediators and neuropsychiatric disease
10:00 – 10:30 AM: BREAK

Session 7: Hepatic Fat Metabolism
Moderator: Gregory A. Graf, PhD, University of Kentucky

10:30 – 11:00 AM: Frank A. Anania, MD, Emory University

  • NASH and gut peptides: why bile matters

11:00 – 11:30 AM: John M Stafford MD, PhD, Vanderbilt University

  • The impact of CETP on hepatic insulin signaling

11:30 – 12:00 AM: Eriks Smagris, MD, UT Southwestern Medical Center

  • Genetics of NAFLD

12:00 – 12:30 PM: Sonja Pijut, Pharm D, University of Kentucky

  • Peripheral oscillators in metabolic disease

12:30 PM: Closing Comments and Adjournment Alan Remaley and Greg Graf